Static List Review Consultation – October 2017
Review of NICE Technology Appraisal Guidance No. 315; Canagliflozin in combination therapy for treating type 2 diabetes
Decision to transfer to the ‘static guidance list’
The Institute was proposing that the guidance should be transferred to the ‘static guidance list’.
After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.
Consequently, the guidance will now be transferred to the static guidance list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.
This page was last updated: 27 October 2017